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Abstract  
Cyclosporine A, an inhibitor of calcineurin, exerts an immunomodulator action interfering with T 
cell activation. Even though novel therapeutic tools have emerged, CyA still represents a suitable 
option in several clinical rheumatology settings. This is the case of refractory nephritis and 
cytopenias associated with systemic lupus erythematosus. Furthermore, CyA is a valued therapeutic 
tool in the management of uveitis and thrombophlebitis in course of Behçet’s disease. Topical CyA 
has been proven to be beneficial in the dry eye of Sjogren’s syndrome, whereas oral treatment with 
CyA can be considered for the severe complications of adult onset Still’s disease. CyA provides a 
therapeutic option in psoriatic arthritis, being rather effective in skin disease. CyA is currently 
regarded as a second-line option for patients with inflammatory myopathies refractory to standard 
regimen. CyA is used even in paediatric rheumatology, in particular in the management of juvenile 
dermatomyositis and macrophage activation syndrome associated with systemic juvenile idiopathic 
arthritis. Importantly, CyA has been shown to suppress the replication of HCV, and it can thus be 
safely prescribed to those patients with chronic hepatitis C. Noteworthy, CyA can be administered 
throughout the gestation course. Surely caution should be paid to CyA safety profile, in particular to 
its nephrotoxicity. Even though most evidence comes from small and uncontrolled studies with few 
randomized controlled trials, CyA should be still regarded as a valid therapeutic tool in 2016 
rheumatology. 
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Introduction 
The earliest use of cyclosporine (CyA) in the field of rheumatology dates back to 1979, when the 
first trial in patients with inflammatory arthritides was conducted [1]. Since then, CyA has been 
used to manage several autoimmune conditions: thanks to its mechanism of action, this 
pharmacological compound is potentially effective in different clinical settings.  
  
Mechanism of action of cyclosporine A 
Initially developed as an anti-mycotic agent, CyA is an 11-aminoacid peptide originally isolated 
from a soil fungus. Its immunosuppressive properties have been described in the 70s, when it was 
first employed as an anti-rejection agent for organ transplantation. CyA is a pro-drug, which 
becomes active after complexing with cyclophillin, an intra-cytoplasmatic protein. The CyA-
cyclophillin complex in turn inhibits calcineurin, a phosphatase that mediates the pharmacological 
effects of CyA. Indeed, calcineurin induces the translocation into the nucleus of the nuclear factor 
of activated T cells (NF-AT), which acts as transcription factor for a number of pro-inflammatory 
cytokines, such as interleukin (IL)-2, IL-2 receptor, IL-4, interferon (IFN)-and transforming 
growth factor– (TGF-). The inhibition of IL-2 and IL-2 receptor, the two main stimulating 
pathways involved in T cell activation, accounts for the action of CyA on T cells: it impairs the 
activation of T helper (Th) cells, even though the T suppressor (Ts) subset may also be affected [2]. 
The pharmacological action of CyA is schematically presented in Figure 1.  
 
Pharmacokinetics of cyclosporine A 
Two formulations of CyA have been developed: the original one (Sandimmune) displays a poor 
bioavailability and larger inter and intra-subject pharmacokinetic variability; the most recent 
microemulsion (Neoral) offers a better bioavailability and a more predictable pharmacokinetics and 
dose linearity. Because of its lipophilic nature, plasma CyA is almost exclusively bound to 
lipoproteins, explaining why CyA serum concentrations might be affected by dietary fat intake. 
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Indeed, raised serum lipid levels can increase CyA total body clearance: a higher serum CyA 
concentration results when the drug is administered before rather than after meals, accounting for 
higher clinical efficacy [2]. 
CyA displays a first-pass effect of 27% in the liver; the enterohepatic recirculation of CyA from the 
bile to the small intestine is responsible of its biphasic distribution. CyA half-life in serum ranges 
between 6 and 24 hours; its oral bioavailability and systemic clearance are controlled by the 
cytochrome P450 and the efflux p-glycoprotein pump, a trans-membrane transporter expressed in 
the gastrointestinal tract and in the liver. CyA metabolites are excreted primarily in the bile, with 
only 6% of the dose being excreted in the urine [2]. 
 
Cyclosporine A in rheumatoid arthritis 
The rationale of CyA use in rheumatoid arthritis (RA) is supported by its mechanism of action: 
besides the inhibition of T cells, CyA has been demonstrated to suppress IL-17 production in vitro. 
This results in the impairment of the differentiation of Th17 cells, a distinct lineage of pro-
inflammatory Th cells regarded as key effectors in RA pathogenesis [3]. The 2008 updated 
guidelines issued by the American College of Rheumatology (ACR) do not enlist CyA as a 
therapeutic option in the management of RA [4]. As a matter of facts, evidences about CyA efficacy 
in RA are not recent, and not so solid to support its routine use (Table 1). Over the years, CyA has 
been proven to be more effective than placebo in disease control [5-9], even at long term [10], 
delaying radiological progression [11-13]. Controlled trials have shown CyA to be as effective as 
parenteral gold [14,15], D-penicillamine [16], hydroxychloroquine (HCQ) and azathioprine (AZA) 
[17-19], but less effective than methotrexate (MTX) [20-22].  
Combining CyA with HCQ, chloroquine or gold has been observed to convey no clear benefit [23-
26]. Conversely, association regimens comprising CyA plus MTX have been demonstrated to allow 
a greater rate of disease control as compared to CyA monotherapy [27-30] and CyA plus 
leflunomide (LEF) [31], using a step-up or a step-down approach. Clinical studies have investigated 
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the combination regimen of CyA plus MTX to MTX alone, reporting a greater beneficial effect for 
the combo approach [32-34], a benefit not sustained on the long-term [35]. Consistently, MTX non 
responder patients have been shown to present a better disease course when randomized to MTX 
plus CyA than when receiving MTX plus placebo [36,37]. On the other hand, the addition of CyA 
to MTX and infliximab (IFX) has been proven to result only in a modest increase in the response 
[38,39], even though CyA plus MTX association regimen has been shown to be effective in 
maintaining disease remission after suspension of treatment with tumour necrosis factor (TNF) 
inhibitors in 62% of patients [40], avoiding even erosive progression at MRI [41]. A 2001 meta-
analysis of randomized controlled trials (RCT) evaluating the optimal step-up strategy in patients 
with an incomplete response to MTX has found that the addition of CyA, etanercept (ETN), IFX or 
LEF results in a comparable ACR20 response at 24-30 weeks of combination therapy [42]. 
 
Cyclosporine A in psoriatic arthritis 
CyA has been shown to be more effective in the management of psoriatic arthritis (PsA) as 
compared to RA [43]. Such observation might be explained by the pivotal role played by IL-17 axis 
in PsA pathogenesis. Furthermore, CyA inhibits vascular endothelial growth factor (VEGF), a key 
mediator of the angiogenesis characteristic of PsA rather than RA synovium [44,45]. In the 2008 
treatment guidelines for PsA, CyA is recommended in the management of moderate or severe 
peripheral arthritis, moderate to severe skin and nail disease [46]. Clinical improvement becomes 
usually evident after 3-4 weeks of treatment with CyA; response of both skin and joint involvement 
is dose-related, with the lowest optimal effective maintenance dose being around 3 mg/Kg. 
Observational studies have shown CyA to exert a beneficial effect in reducing peripheral (but not 
axial) joint involvement in patients with PsA [47-50]. Controlled trials have reported that CyA is as 
effective as MTX, but with a higher withdrawal rate [51], and more effective than sulfasalazine 
(SSZ) [52]. The association of CyA with MTX has been shown to lead to a significantly better joint 
disease control than MTX alone [53]; the addition of CyA to ETN in patients with PsA and 
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uncontrolled cutaneous disease has emerged to be a safe and effective therapeutic option [54], being 
even better on psoriatic skin involvement than ETN plus MTX [55]. Response to CyA in PsA has 
been found to be persistent at two-year follow-up [56], controlling also the radiological damage 
[57]. Clinical studies on CyA in PsA are detailed in Table 2. 
 
Cyclosporine A in systemic lupus erythematosus 
In vivo, treatment with CyA has been found to prolong the life span of NZB/W F1 mice, reducing 
anti-DNA antibody titers [58-60]. The earliest experience with CyA treatment in patients with 
systemic lupus erythematosus (SLE) dates back to 1981; nowadays, CyA is not so commonly 
prescribed to lupus patients. In several small observational studies, CyA, alone or in combination 
with other agents, has been shown to reduce disease activity and improve immunological 
parameters such as anti-dsDNA titers and complement levels, allowing steroid tapering [61-
69](Table 3). In particular, CyA has been shown to be beneficial in some lupus manifestations, and 
it might be taken into account as therapeutic option in refractory lupus nephritis, skin disease and 
haematological involvement [70]. CyA efficacy in lupus nephritis is mediated not only by its 
immunosuppressive action but also its ability to stabilize the podocyte cytoskeleton by inhibiting 
dephosphorylation and degradation of synaptopodin, an actin-associated protein that regulates cell 
shape and motility and mediates podocyte foot processes. To note, synaptopodin downregulation 
and increased calcineurin activity are both associated with proteinuric glomerular diseases [71,72]. 
CyA is currently recommended in the management of lupus nephritis with persistent severe 
proteinuria, refractory to conventional treatment with corticosteroids and cytotoxic agents [70]. 
Indeed, according to still limited data, the association of CyA with corticosteroid therapy is effec-
tive in the treatment of class III, IV or V lupus nephritis. Most evidence suggests CyA efficacy in 
proliferative lupus nephritis, as supported by few case series [66,73-78] and uncontrolled trials 
[79,80]. In addition, CyA has been shown to be more beneficial than steroids alone [81] and as 
effective as AZA [82] and cyclophosphamide (CTX), both at short [83] and long term follow-up 
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[84]. As a whole, it can be stated that CyA treatment in proliferative lupus nephritis displays a 
cumulative rate of complete or partial remission approaching 90%, with an important anti-
proteinuric effect [85]. CyA has been proven to be effective also in the management of 
membranous lupus nephritis, even though evidence comes from small retrospective studies [86-89] 
and a single RCT comparing CyA to CTX as adjunctive treatments to steroids [90]. A 2014 meta-
analysis considering CyA and tacrolimus has concluded that calcineurin inhibitors might be 
regarded as a reasonable alternative to CTX in the induction treatment of active lupus nephritis, 
with an higher rate of complete remission (relative risk [RR]=1.56) and a better response/total 
remission ratio (RR=1.23) [91]. On the other hand, when evaluating prescription of CyA in lupus 
nephritis, it should be mentioned that in a cross-sectional study on 64 patients with lupus nephritis, 
CyA treatment has emerged as a risk factor for arterial hypertension, conveying a odds ratio of 5.3 
[92].  
Haematological abnormalities, if relapsing or refractory to steroids, have been shown to respond 
well to CyA. This is the case of lupus-associated thrombocytopenia [93,94], haemolytic anaemia 
[95], aplastic anaemia [96], red cell aplasia [97-99] and haemophagocytic syndrome [100]. 
Unfortunately, literature is still limited to case reports and small case series. 
CyA exerts an evident steroid-sparing effect in cutaneous lupus. Unfortunately, skin disease has not 
provided a primary outcome measure in most studies in SLE; however, cutaneous manifestations 
have been reported to improve upon CyA treatment  [65,68]. In addition, there are case reports of 
CyA efficacy in subacute cutaneous lupus erythematosus (LE) [101] and LE profundus [102], but 
not in discoid LE [103,104].  
 
Cyclosporine A in systemic sclerosis 
In vitro, CyA has been observed to inhibit the pro-fibrotic effects induced by TGF-β and IL-4 in 
fibroblasts, leading to a decreased synthesis of collagen [105-107]. Although there is a rationale for 
its use, data in support of the efficacy of CyA in systemic sclerosis (SSc) are not solid (Table 4). 
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CyA has been reported to significantly improve skin thickening in some, but not all, scleroderma 
patients; available evidence comes from small, short-term studies [69,108-111]. In particular, an 
improvement of oesophageal motor function has emerged with CyA treatment [111,112]; 
conversely, CyA has been described not to affect scleroderma-related internal organ involvement, 
in particular lung and cardiac disease [108]. There is a single report of the benefit of CyA in 
interstitial lung disease (ILD): one patient with diffuse scleroderma received CyA as maintenance 
therapy after CTX pulses, with evidences of stable disease at two-year clinical and radiological 
follow-up [113]. It is thus not surprising that the guidelines for scleroderma treatment published by 
the European League Against Rheumatism Scleroderma Trials and Research Group have not 
recommend CyA in SSc, highlighting the need of larger prospective studies [114]. It should be 
noted that CyA use in SSc is limited by its nephrotoxicity: indeed, CyA might affect renal function 
through a direct toxic action on the nephron or through an impairment of renal haemodynamic 
homeostasis. Consequently, CyA may not only worsen arterial hypertension, but also precipitate 
acute renal failure. In the past, CyA has even been proposed as risk factor for scleroderma renal 
crisis, but such association has not been confirmed in later studies [115]. 
 
Cyclosporine A in inflammatory myopathies 
In the setting of inflammatory myopathies (polymyositis [PM] and dermatomyositis [DM]), CyA is 
currently regarded as a second-line option to be reserved to patients with disease refractory to 
standard regimen, which includes high-dose prednisone plus MTX or AZA.    
Few trials have investigated CyA efficacy in inflammatory myopathies (Table 5). In a prospective 
controlled study, 10 DM patients receiving CyA have achieved a prompt remission; therapeutic 
failure occurred in 10% of cases as compared to 9% in those treated with standard regimen [116]. In 
addition, in a RCT on 36 patients (20 with DM, 16 with PM), CyA has been shown to be as 
effective as MTX [117]. In literature there are reports about CyA efficacy in managing DM-
associated oesophageal involvement [118]. A growing body of evidence suggests the beneficial 
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effect of CyA in the management of ILD [119-123], also in cases resistant to steroid treatment 
[124,125] and those with an acute onset [126]. In particular, disease stabilization -or even an 
increase greater than 10% in forced vital capacity- has been reported in all series. CyA has also 
been compared to CTX in the management of PM/DM-ILD: in a cohort of 15 anti-Jo1-positive 
patients with lung involvement, high resolution scan of the chest at 12-month follow-up has 
revealed a disease worsening in 71% of patients treated with CyA as compared to 50% of those 
receiving CTX, with no differences in CT changes [127].    
 
Cyclosporine A in systemic vasculitides 
CyA is not enlisted as a therapeutic option in the current guidelines for the management of anti-
neutrophil cytoplasmic antibody (ANCA)-associated vasculitides: the evidence of CyA efficacy in 
these clinical settings is rather scarce (Table 6). There are only anecdotal reports of patients with 
refractory granulomatosis with polyangiitis (GPA, formerly known as Wegener granulomatosis) 
successfully treated with CyA. In particular, CyA has led to the improvement of renal function and 
to the complete resolution of lung lesions [128-130], while in other cases CyA has not been 
effective in achieving disease remission [131]. A single report of CyA in eosinophilic 
granulomatosis with polyangiitis (EGP, formerly known as Churg-Strauss syndrome) has been 
published: a patient with EGP resistant to treatment with pulse intravenous CTX responded well to 
CyA therapy [132].  
Similarly, the burden of evidence suggesting CyA efficacy in large vessels vasculitides is poor. In a 
RCT, CyA has been evaluated as steroid sparing agent in 22 patients with giant cells arteritis. 
However, the addition of CyA to corticosteroid treatment does not appear to be beneficial [133-
135]. CyA has been successfully used in the management of patients with Takayasu’s arteritis 
[134,136], in particular in those subjects with severe pyoderma gangrenosum [137,138]. 
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Cyclosporine A in Behçet’s disease  
The efficacy of CyA in Behçet’s Disease (BD) is supported by the inhibition of IL-1, a key-
cytokine in disease pathogenesis [139]. Given the wide heterogeneity in the clinical manifestations 
of BD, the therapeutic approaches might be rather diverse, depending upon the presenting 
symptoms. Even though CyA has been shown to be effective in almost all clinical manifestations of 
BD, its use is currently recommended in the management of refractory ocular involvement and 
thrombophlebitis [140] (Table 7). In particular, refractory eye disease provides the main setting for 
CyA prescription in BD. Indeed, CyA is the agent of choice, alternatively to IFX, in the 
management of eye involvement not responsive to standard treatment, to be prescribed in 
combination with AZA and corticosteroids [140]. This recommendation is supported by three RCT 
concordantly showing CyA efficacy in ocular involvement [141-143], even though to a lower extent 
than IFX [144]. To note, CyA is rapidly effective in acute uveitis, although the beneficial effects 
seem to be not sustained in the long term [145,146]. 
CyA is currently recommended also in the management of thrombophlebitis, based on an open trial 
showing complete resolution of venous insufficiency with no recurrences over a two-month follow-
up in seven patients [147]. In addition, CyA has been demonstrated to be effective in case of ulcers, 
oral as well as genital, and erythema nodosum, being superior to colchicine [143,148]. However, 
CyA is regarded as fourth-line agent because of its toxicity profile. In particular, because of its 
neurotoxicity, CyA should be not prescribed to BD patients with central nervous system 
involvement, unless necessary to manage intraocular inflammation [140]. CyA neurologic side 
effects in BD have been confirmed in three case-controlled studies [149-151].  
 
Cyclosporine A in adult onset Still’s disease  
Corticosteroids still provide the mainstay of treatment of adult onset Still’s disease, and MTX is the 
first-line steroid-sparing option. Targeted biologic agents, mainly IL-1 antagonists and TNF- 
inhibitors, are reserved to refractory cases [152]. Even though there are reports of CyA efficacy as 
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steroid sparing agent with a rapid effect and a low recurrence rate [153], its use in adult onset Still’s 
disease is currently limited to some of the severe manifestations of Still’s disease [154]. Indeed, 
CyA, alone or in combination with other pharmacological tools, might be considered as an option in 
the management of disseminated intravascular coagulation [155,156], macrophage activation 
syndrome (MAS) [157,158], acquired amegakariocytic thrombocytopenia [159] and severe hepatic 
failure [160]. Details of studies investigating CyA in adult onset Still’s disease are presented in 
Table 8. 
 
Cyclosporine A in Sjogren’s syndrome 
Ex vivo studies have showed that topical CyA therapy induces a reduction in the number of 
activated T lymphocytes and apoptotic cells in conjunctival biopsies, a decreased expression of pro-
inflammatory cytokines and a raise in goblet cell epithelial density [161-163]. Topical CyA is 
currently recommended in the management of dry eye (symptoms severity of level 2) associated 
with Sjogren’s syndrome, at the dose of one drop in each eye twice daily [164]. Indeed, almost all 
available RCT have reported topical CyA to improve symptoms and signs of ocular sicca syndrome 
as compared to placebo or alternative treatment [165-169]. No clear dose-response relationship 
could be identified, but CyA 0.05% and 0.1% emulsions are the preparations most commonly 
prescribed. 
Oral CyA has been evaluated in a single double-blind study conducted in a cohort of 20 patients, 
with a significant improvement of xerostomia and no significant differences in the Schirmer test 
score [170,171]. Details of studies investigating CyA in Sjogren’s syndrome are presented in Table 
9. 
 
Cyclosporine A in paediatric rheumatology 
CyA is currently used even in the field of paediatric rheumatology, with two particular indications:  
juvenile DM (JDM) and systemic juvenile idiopathic arthritis (sJIA). Few small retrospective 
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studies and case series have investigated the beneficial effects of CyA in JDM. Even though 
corticosteroids are the only agents currently approved by the US Food and Drug Administration for 
JDM, many patients require additional immunosuppressive medications. In JDM patients 
unresponsive to corticosteroids or immunosuppressive drugs (MTX, AZA or CTX), CyA treatment 
has resulted in the improvement of muscle strength, allowing steroid tapering [172-174]. None of 
the immunosuppressive drugs have been yet evaluated in controlled trials in children; a 5-year, 
phase-III, single-blind, randomized, controlled trial is currently on-going. It envisages 3 treatment 
arms: i) prednisone; ii) prednisone plus MTX and iii) prednisone plus CyA. This international trial 
involves 185 partners from 46 countries, coordinated by PRINTO (Pediatric Rheumatology 
International Trials Organisation) and conducted in children with newly diagnosed JDM. An 
analysis of primary outcome measures after 6 months of treatment has showed that time to inactive 
disease is significantly shorter and time to major therapeutic changes significantly longer in the 
combination groups compared to prednisone alone. The highest rate of adverse events has been 
registered in the group treated with CyA (51%) compared to MTX (28%) or prednisone alone 
(21%) [175].  
The guidelines issued by ACR in 2013 recommends CyA as third-line treatment for sJIA children 
with active systemic features and a physician global assessment higher than 5 [176]. This 
recommendation is based upon prospective and retrospective series that have showed that CyA is 
effective in treatment of sJIA, leading to improvement in laboratory variables, joint counts, joint 
swelling, and morning stiffness in some -but not all- children, even if the improvement is not 
sustained at long term [173,174,177,178]. CyA has been evaluated even as second-line tool in sJIA, 
showing a good efficacy when associated with MTX [179]. CyA is particularly effective in MAS, a 
potentially life-threatening complication occurring in 7-13% of sJIA patients. Evidence of CyA 
efficacy in MAS associated with sJIA relies upon observational studies and case series (Table 10). 
CyA has been proven to result in clinical improvement in most patients, being particularly effective 
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in the management of systemic symptoms [180-187]. Importantly, CyA has been reported life-
saving in serious cases of steroid resistant MAS [180]. 
 
Cyclosporine A and hepatitis C virus 
CyA has been reported to suppress the replication of hepatitis C virus (HCV) both in vitro and in 
vivo, in a dose-dependent manner [188]. Such effect is mediated by the inhibition of cyclophillin B 
[189]. The maximum inhibitory effect exerted by CyA is similar to that of IFN-; to note, these two 
agents are certainly additive and possibly synergistic [190]. In addition CyA displays an anti-
fibrotic effect inhibiting collagen production and increasing collagenase activity in hepatic stellate 
cells [191]. These data account for the safety and efficacy of CyA in the treatment of patients with 
autoimmune disorders and concomitant chronic HCV infection, as documented by some case-series 
with improvement of liver function and decreased viral load [192,193]. Furthermore, CyA safety in 
HCV positive RA patients has been evaluated in combination with anti-TNF- agents, without any 
significant adverse event [194]. 
 
Cyclosporine A and pregnancy 
CyA, being highly lipophilic, crosses the placenta to achieve in the fetal circulation a 10-50% 
concentration of that in maternal plasma. Animal studies have not shown increased malformation 
rates, but in utero exposure to CyA in rabbits induces a nephron reduction leading to systemic 
hypertension and progressive chronic renal insufficiency in adulthood [195]. These in vivo 
observations explain why the FDA currently classifies CyA in the pregnancy risk category C. 
Data on CyA in pregnancies are mostly derived from registries of pregnant transplant recipients, 
with more than 5000 observed pregnancies. Most studies of pregnancies exposed to CyA have 
concluded that there is no evidence for teratogenicity. On the other hand, an increase in premature 
delivery and low birth weight has been described, with 56% and 43% prevalence rates in a meta-
analysis of 15 studies [196]. It is still not clear whether prematurity and low birth weight are 
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actually due to CyA therapy or rather related to the underlying disease. Conversely, experience in 
pregnant patients with autoimmune disease is limited to case reports and case series accounting for 
about 50 pregnancies. No increase of congenital malformations or any particular malformation 
pattern has emerged; however, a higher incidence of low birth weight and prematurity has been 
described in CyA-treated women with autoimmune diseases as compared to the general population, 
even though to a lesser extent than in transplanted women [197]. A 12-year follow-up of 175 
children exposed to CyA in utero has showed a 16% incidence of mental developmental delay, 
which might be attributed to the high incidence of prematurity [198]. Other studies have shown that 
maternal treatment with CyA during pregnancy does not permanently affect the foetal immune 
system [199,200]. As a whole, CyA is considered to be safe during pregnancy, therefore treatment 
can be continued at the lowest effective dose throughout the entire gestation. A periodic control of 
maternal blood pressure and renal function should be performed on a regular basis.  
 
Cyclosporine A and breastfeeding 
CyA is excreted in breast milk, with a wide variation in the milk-to-maternal serum concentration 
ratio, depending on the time of sampling and maternal dose. To date, evidence on the safety of 
breastfeeding during CyA therapy is limited to small case series and case reports [201,202]. No 
adverse events related to maternal CyA treatment during lactation have been described, with CyA 
being undetectable in almost all cases. Even though these data are reassuring, evidence is limited 
and still inconclusive. To date, breastfeeding during CyA treatment is not recommended because of 
theoretical risks of immunosuppressive effects in the neonate [203]. 
 
Side effects   
In a study involving 154 patients with RA, a dose-related decrease in glomerular filtration rate with 
corresponding increase in serum creatinine has emerged as the most frequently reported side-effect 
of CyA (48%); after drug discontinuation, creatinine returns within 15% of baseline in almost all 
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cases [204]. There is a wide variety in the incidence of new-onset arterial hypertension, which 
ranges from 0 to 57% across available studies. Gastrointestinal symptoms, including nausea, 
abdominal pain, diarrhoea and vomiting, have been described in less than 5%. Hepatotoxicity 
(presenting as elevation of hepatic enzymes and bilirubin) usually occurs at higher dosages than 
those used in rheumatology. Neurologic side effects of CyA include headache, tremor, seizure 
psychosis, paraesthesias, and sleep disturbances; paraesthesias and tremor can occur in up to 40% 
of patients. Gingival hyperplasia has been reported in up to 30% of patients on CyA; cutaneous side 
effects comprise hypertrichosis, epidermal cyst, keratosis pilaris, and sebaceous hyperplasia. 
Hypertrichosis is rather frequent, presenting in up to 60% of patients. Hyperlipidemia, in particular 
hypertriglyceridemia, can present in up to 15% of patients [205,206]. Based on epidemiologic 
analyses, FDA warns about a relationship between CyA and malignant lymphomas among RA 
patients and about  an increased hazard of skin and lymphoproliferative malignancies among 
patients with psoriasis receiving CyA, even though the relative risk is similar to subjects treated 
with other immunosuppressive agents [207]. To date, there is no evidence that CyA predisposes to 
solid malignancies; large controlled studies have even suggested an immunoprotective action of 
CyA with a decreased OR for breast and colon neoplasias [204]. Table 11 reports the toxicity 
profile of CyA in RA patients. 
 
Drug interactions 
Table 12 reports the pharmacological compounds interfering with CyA pharmacokinetics. As CyA 
is mainly metabolized by cytochrome P450, drugs that induce hepatic enzyme metabolism lower 
CyA concentrations, while drugs that inhibit hepatic metabolism raise CyA blood concentrations. 
Older age, concomitant renal failure, arterial hypertension and dehydration might also contribute to 
enhance the nephrotoxicity of CyA [206]. 
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Drug safety monitoring 
Due to CyA nephrotoxicity, serum creatinine and blood pressure should be checked on at least two 
occasions to obtain a baseline value prior to therapy. Both creatinine and blood pressure should be 
monitored fortnightly during the first 3 months of treatment and monthly thereafter. Dose reduction 
of 0.5-0.75 mg/kg/day is warranted if serum creatinine increases above baseline by 30% -even if 
still in the normal range- or if uncontrolled hypertension supervenes. When creatinine increases by 
more than 50% of baseline, the daily dose dosage should be reduced by 50%; if this reduction does 
not affect the creatinine value, the drug should be discontinued. If arterial hypertension develops, 
the use of anti-hypertensive agents should be considered, avoiding potassium-sparing diuretics 
because of the risk of hyperkaliemia. In case of hyperlipidemia, a lipid-lowering diet should be 
commenced and a lipid-lowering agent introduced. Since CyA decreases the clearance of statins, 
rhabdomyolisis may occur, thus warranting strict vigilance. Given that in patients with autoimmune 
diseases a poor correlation between CyA blood levels and its clinical effect has been noted, the 
monitoring of CyA plasma concentration is not routinely required [205,206]. 
 
Conclusion 
CyA exerts a valid immunomodulator action, being effective in the treatment of many autoimmune 
diseases. Even though novel therapeutic tools have emerged over the recent years, CyA still 
represents a suitable option in several clinical settings: 
a) In SLE, refractory lupus nephritis and cytopenias have been reported to respond well to 
CyA; 
b)  In PsA, CyA can be listed as a therapeutic option, being rather effective in cutaneous 
disease; 
c) In BD, CyA is a valued treatment tool in the management of uveitis and thrombophlebitis; 
d) In adult onset Still’s disease, treatment with CyA can be considered for the most severe 
complications such as disseminated intravascular coagulation and MAS;  
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e) In dry eye disease, topical CyA has been proven to be beneficial; 
f) In inflammatory myopathies, CyA is currently regarded as a second-line option to be 
reserved to patients with disease refractory to standard regimen; 
g) In paediatric rheumatology, CyA is used in the management of JDM and MAS associated 
with sJIA.  
Conversely, CyA seems to exert an overall poor beneficial effect in SSc, Sjogren’s syndrome 
and systemic vasculitides. CyA can be considered as an anchor drug in particular clinical 
situations: 
a) HCV-positive patients: CyA has been shown to suppress the replication of HCV, and it can 
thus be administered to those patients with HCV; 
b) Pregnancy: CyA can be safely prescribed throughout the gestation course, providing a 
pharmacological option in pregnant women with an active autoimmune disease.  
Surely caution should be paid to CyA safety profile, in particular because of its nephrotoxicity: 
prescribing this drug should be avoided in patients with a raised baseline creatinine level and 
uncontrolled hypertension. Unfortunately, most of available evidence about CyA efficacy in 
rheumatology comes from small and uncontrolled studies, with very few RCT. Nevertheless, 
available data are encouraging, supporting CyA as a corticosteroid-sparing action in many 
rheumatologic conditions: despite being regarded as an “out-of-fashion” drug, CyA should be 
still part of therapeutic armamentarium of rheumatologists, even in 2016.  
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Figure 1. Mechanism of action of cyclosporine A.  
CyA= cyclosporine A; Ca2+= calcium; NF-ATc-P= phosphorylated cytoplasmic nuclear factor of 
activated T-cells; NF-ATc= cytoplasmic nuclear factor of activated T-cells; NF-ATn= nuclear 
nuclear factor of activated T-cells; IL-2= interleukin 2.  
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Table 1. Clinical studies on cyclosporine A in rheumatoid arthritis. 
Author [Ref] Year 
Study 
design 
 
CyA dose 
 
Follow-up 
N of 
patients 
Treatment groups Outcome 
Dougados [5] 1987 CS 5 mg/Kg/day 12 months 12 CyA Good clinical efficacy 
 
Førre  
[19] 
 
1987 CC 10 mg/Kg/day 26 weeks 24 
CyA 
AZA  
CyA group: improvement in 
Ritchie index, PI joint 
circumferences, 50-foot walk 
time, grip strength 
AZA group: improvement in grip 
strength 
Weinblatt [7] 1987 CS 6 mg/Kg/day 24 weeks 
 
10 
 
CyA 
Significant improvement in joint 
pain, joint swelling indexes, 
patient and physician assessments 
Dougados [6] 1989 CS 5 mg/Kg/day 12 months 49 
CyA 
 
CyA discontinued in 32 patients 
because of inefficacy or side-
effects 
In 17 patients still receiving CyA, 
significant clinical improvement 
persisted at 12-month evaluation 
Tugwell [9] 
 
1990 RCT 2.5 mg/Kg/day 6 months 144 
CyA 
Placebo 
Significant improvement in CyA 
group compared to placebo group 
in joint pain, active joint count, 
functional status.   
van Rijthoven [10] 1991 RCT 5 mg/Kg/day 24 weeks 92 
CyA 
D-penicillamine  
CyA and D-penicillamine equally 
effective 
Ahern  
[18] 
1991 RCT 4.2 mg/Kg/day 6 months 52 
CyA 
AZA  
CyA and AZA equally effective 
van Rijthoven [16] 
 
1991 CS 5 mg/Kg/day 6 months 16 CyA 
CyA discontinued in 6 patients 
because of inefficacy or side-
effects 
In 12 patients still receiving CyA, 
significant clinical improvement 
in all considered variables. 
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Madhok 
[8] 
1991 CS 5 mg/Kg/day 24 months 20 CyA 
Significant improvement in 
Ritchie index, joint pain, CRP, 
joint function 
 
Bensen 
[28] 
 
1994 CC 2.5 mg/Kg/day 12 months 40 
CyA + gold 
CyA + MTX 
Increased efficacy with the 
addition of CyA to gold or MTX  
Kruger 
[17] 
 
1994 RCT 5 mg/Kg/day 6 months 117 
CyA 
AZA  
CyA and AZA equally effective 
Førre 
[13] 
 
1994 RCT 5 mg/Kg/day 48 weeks 122 
CyA 
Placebo 
Slower radiologic progression in 
CyA group 
Tugwell  
[30] 
 
1995 RCT 
2.5-5 
mg/Kg/day 
6 months 148 
CyA + MTX 
MTX + placebo 
CyA + MTX more effective than 
MTX + placebo in severe RA  
Salaffi 
[29] 
 
1996 CC 2.5 mg/Kg/day 6 months 28 
CyA + HCQ 
CyA + MTX 
CyA + MTX more effective and 
with more side-effects than CyA 
+ HCQ  
Pasero 
[12]   
 
1996 RCT 3 mg/Kg/day 12 months 361 
CyA 
Antimalarials 
Gold 
SSZ 
Slower radiologic progression in 
CyA group compared to DMARD 
group 
Bendix  
[25] 
 
1996 RCT 2.5 mg/Kg/day 6 months 40 
CyA + Gold 
Gold + placebo 
CyA + gold as effective as gold + 
placebo 
Stein 
[36]    
 
1997 CC 2.5 mg/Kg/day 48 weeks 92 CyA + MTX 
Clinical improvement with the 
addition of CyA to MTX 
Van de Borne 
[26] 
 
1998 RCT 
1.2.5 
mg/Kg/day 
24 weeks 88 
CyA + chloroquine 
Chloroquine + placebo 
CyA + chloroquine moderately 
more effective than chloroquine + 
placebo 
Zeidler 
[14] 
1998 RCT 3 mg/Kg/day 18 months 375 
CyA 
Gold  
CyA and gold equally effective 
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Drosos  
[21] 
 
1998 RCT 3 mg/Kg/day 24 months 103 
CyA 
MTX  
CyA and MTX equally effective 
Proudman  
[208] 
 
2000 RCT 1.5 mg/Kg/day 48 weeks 82 
CyA + MTX + i.a. steroids 
SSZ 
Similar remission rate in the CyA 
+ MTX + steroid group and in the 
SSZ group 
Drosos 
[11]    
 
2000 RCT 3 mg/Kg/day 24 months 103 
 
CyA + PDN  
MTX + PDN 
CyA and MTX equally effective 
in preventing radiological 
progression 
Ferraccioli  
[37] 
2002 
CC 3 mg/Kg/day 18 months 126 
CyA, then CyA + MTX 
MTX, then CyA + MTX 
SSZ 
CyA + MTX + SSZ 
CyA + MTX + SSZ effective in 
control disease activity 
Marchesoni 
[22] 
 
2002 RCT 3 mg/Kg/day 24 months 57 
CyA + MTX, then CyA 
CyA + MTX, then MTX 
MTX more effective than CyA in 
control disease activity 
Gerards  
[27] 
 
2002 RCT 2 mg/kg/day 48 weeks 120 
CyA 
CyA + MTX 
CyA + MTX more effective than 
CyA in improving disease 
activity and slowing radiologic 
progression 
Kvien 
[15] 
 
2002 RCT 5 mg/kg/day 36 months 278 
CyA 
Gold 
CyA and gold equally effective in 
preventing radiological 
progression 
Temekonidis 
[39] 
 
2002 CS 2 mg/kg/day 12 months 18 CyA + IFX + PDN  
Clinical improvement with the 
addition of CyA to IFX 
Marchesoni 
[33] 
2003 RCT 3 mg/kg/day 12 months 61 
CyA + MTX 
MTX 
CyA + MTX more effective than 
MTX in improving disease 
activity and slowing radiologic 
progression 
Miranda 
[24] 
2004 RCT 
2.5-5 
mg/kg/day 
12 months 149 
CyA + chloroquine 
CyA + placebo 
 
CyA + chloroquine as effective as 
CyA + chloroquine 
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Sarzi Puttini 
[23] 
 
2005 RCT 3 mg/kg/day 12 months 105 
CyA 
CyA + MTX 
CyA + HCQ 
CyA + MTX more effective than 
CyA and CyA + HCQ in 
improving disease activity and 
slow radiologic progression 
Karanikolas 
[31] 
 
2006 RCT 
2.5-4.6 
mg/kg/day 
12 months 106 
CyA + LEF 
CyA 
LEF 
CyA + LEF more effective than 
monotherapy 
Sidiropoulos  
[38] 
 
2006 
CS 
2.5-3 
mg/kg/day 
24 weeks 19 CyA + MTX + IFX 
Modest response with CyA + IFX 
+ MTX 
Choy  
[34] 
2008 RCT 3 mg/kg/day 24 months 467 
CyA + MTX 
MTX + steroids 
CyA + MTX + steroids 
CyA + MTX + steroids more 
effective than CyA + MTX and 
MTX + steroids in slowing 
radiologic progression 
Bejarano 
[209] 
2008 RCT 1.5 mg/Kg/day 7 years 82 
CyA + MTX + i.a. steroids 
SSZ 
Better outcome with CyA + MTX 
+ i.a. steroids than with SSZ 
Migliore 2010 
[40] 
 
2010 CS 2-3 mg/kg/day 6 months 23 IFX + CyA + MTX 
CyA + MTX effective in 
maintaining disease remission 
obtained with IFX 
Hetland  
[35] 
2010 RCT 4 mg/Kg/day 5 years 139 
CyA + MTX + HCQ 
MTX + HCQ + placebo 
No clinical benefit from CyA as 
compared to placebo 
Bakker 
[20] 
 
2010 CC 4 mg/Kg/day 3 months 151 
CyA + oral MTX 
s.c. MTX 
s.c. MTX better than CyA + oral 
MTX in controlling disease 
activity 
Picchianti Diamanti 
[41] 
2012 PC 
2-3 
mg/Kg/day 
12 months 7 CyA + MTX 
CyA + MTX effective in 
maintaining clinical remission 
after ETN suspension 
 
CyA: cyclosporine A; MTX: methotrexate; AZA: azathioprine; SSZ: sulphasalazine; HCQ: hydroxychloroquine; DMARD: disease-modifying anti-
rheumatic drug; PDN: prednisone; IFX: infliximab; ETN: etanercept; CS: case-series; CC: case-control; RCT: randomized controlled trial; CRP: C 
reactive protein; PI: proximal inter-phalangeal joints; i.a.: intra-articular; s.c.: subcutaneous.  
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Table 2. Clinical studies on cyclosporine A in psoriatic arthritis.  
 
Author [Ref] Year 
Study 
design 
CyA dose Follow-up 
N of 
patients 
Treatment groups Outcome 
Gupta 
[47] 
1989 CC 6 mg/Kg/day 8 weeks 6 CyA 
CyA effective in controlling joint and 
skin disease 
Steinsson 
[48] 
1990 CS 3.5 mg/Kg/day 6 months 8 CyA 
CyA effective in controlling joint and 
skin disease 
Salvarani 
[49] 
1992 CS 3 mg/Kg/day 6 months 12 CyA 
CyA effective in controlling joint and 
skin disease 
Spadaro 
[51] 
1995 RCT 3-5 mg/Kg/day 12 months 35 
CyA 
MTX 
CyA as effective as MTX in disease 
control 
Mahrle 
[50] 
1996 CS 2.7 mg/Kg/day 6 months 55 CyA 
CyA effective in controlling joint and 
skin disease 
Macchioni 
[57] 
1998 PC 3 mg/Kg/day 24 months 24 CyA 
CyA effective in controlling radiological 
disease progression in 60% of patients 
Salvarani 
[52] 
2001 RCT 3 mg/Kg/day 24 weeks 99 
CyA 
SSZ  
Symptomatic therapy 
CyA more effective than SSZ and 
symptomatic therapy in disease control 
Sarzi-Puttini 
[56] 
2002 PC 3 mg/Kg/day 24 months 60 CyA CyA effective in disease control 
Fraser 
[53] 
2005 RCT 2.5 mg/Kg/day 12 months 72 
CyA + MTX 
MTX + placebo 
CyA + MTX more effective than MTX + 
placebo in disease control 
D’Angelo 
[54] 
2010 PC 3 mg/Kg/day 24 week 103 CyA + ETN CyA + ETN effective in disease control 
Atzeni 
[55] 
2011 RCT 3 mg/Kg/day 6 months 41 
CyA + ETN 
MTX + ETN 
CyA + ETN as effective as MTX + ETN 
in controlling joint disease but more 
effective in controlling skin disease 
 
CyA: cyclosporine A; MTX: methotrexate; SSZ: sulphasalazine; ETN: etanercept; CS: case-series; CC: case-control; RCT: randomized controlled 
trial; PC: prospective cohort.  
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Table 3. Studies on cyclosporine A in systemic lupus erythematosus.  
 
 
Author [Ref] Year 
Study 
design  
CyA dose 
Clinical 
manifestations 
Follow-up N of 
patien
ts 
Treatment 
group(s) 
Outcome 
Isenberg 
[61] 
 
1981 CS 
10 
mg/Kg/day 
Disease activity 7 weeks 5 CyA + steroids 
CyA effective in the 
management of arthralgias in 
two patients, no improvement in 
three patients 
Feutren 
[62] 
 
1987 CS 
5 
mg/Kg/day 
Disease activity 12 months 13 CyA 
CyA effective in reducing 
disease activity in 62% of 
patients 
Heule 
[103] 
1986 CR 
5.3 
mg/Kg/day 
Discoid LE 10 weeks 1 CyA + steroids 
CyA + steroids not effective in 
the management of discoid LE 
Miescher 
[63] 
 
1988 CS 
5 
mg/Kg/day 
Disease activity 
Diffuse proliferative 
glomerulonephritis 
27.1 
months 
14 CyA + steroids 
CyA effective in reducing 
disease activity and improving 
kidney function 
Favre 
[73] 
1989 PC 
5 
mg/Kg/day 
Unresponsive lupus 
nephritis 
52 months 26 CyA + steroids 
CyA effective in reducing 
disease activity and improving 
renal function as well as 
proteinuria in 90% of patients 
Balletta 
[81] 
1992 CC 
1.5 
mg/Kg/day 
Active lupus nephritis 12 months 10 
Steroids 
CyA + steroids 
CyA + steroids more effective 
than steroids alone in the 
management of active lupus 
nephritis 
Hussein 
[74] 
1993 CS 
2.24-4.2 
mg/Kg/day 
Lupus nephritis 35 months 5 CyA + steroids 
Systemic and renal flares in 3 of 
5 patients  
Radhakrishnan 
[86] 
1994 CC 
4-5 
mg/Kg/day 
Membranous lupus 
nephritis 
43 months 10 CyA + steroids 
CyA + steroids effective in the 
management of nephritic 
syndrome in patients with 
membranous lupus nephropathy 
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Miescher 
[67] 
 
1994 CS 
5 
mg/Kg/day 
Disease activity 7.1 years 73 
CyA + steroids 
+/- MTX +/- 
CTX 
CyA (+/- MTX +/- CTX) 
effective as steroid-sparing agent  
Yell 
[104] 
1994 CR 
3.8-4 
mg/Kg/day 
Discoid LE 24 weeks 2 CyA 
CyA effective in the 
management of discoid LE 
Tokuda 
[64] 
1994 CS 
3 
mg/Kg/day 
SLE 20 weeks 10 CyA 
CyA effective in reducing 
disease activity and anti-dsDNA 
antibody titers 
Grabbe 
[101] 
1995 CR 
2.5 
mg/Kg/day 
Subacute LE 12 weeks 1 CyA 
CyA effective in the 
management of subacute LE 
Manger 
[75] 
1996 CS 
3-5 
mg/Kg/day 
SLE 64 months 16 CyA 
CyA effective in controlling 
lupus manifestations 
Caccavo 
[65] 
1997 CS 
2.5-3.5 
mg/Kg/day 
SLE 24 months 30 CyA 
CyA effective in controlling 
lupus manifestations 
Sugiyama 
[210] 
1998 CR 
1 
mg/Kg/day 
Thrombocytopenia NR 2 CyA + steroids 
CyA effective in the 
management of 
thrombocytopenia 
Dostal 
[66] 
 
1998 CS 
5 
mg/Kg/day 
Disease activity 
Lupus nephropathy 
12 months 11 CyA + steroids 
CyA effective in reducing 
SLEDAI score, ANA and anti-
dsDNA titres, renal histological 
disease activity and proteinuria 
Tam 
[76] 
1998 PC 
5 
mg/Kg/day 
Type IV lupus nephritis 12 months 17 CyA + steroids 
CyA + steroids effective in the 
long-term management of type 
IV lupus nephritis 
Saeki 
[102] 
2000 CR 
4 
mg/Kg/day 
Lupus profundus 3 years 1 CyA + steroids 
CyA effective in the treatment of 
lupus profundus 
Bambauer 
[211] 
2000 CS 
1-2 
mg/Kg/day 
SLE 5 years 28 
CyA + PE + 
steroids + 
AZA +/- CTX 
CyA effective in controlling 
lupus manifestations when 
associated with PE + steroids + 
AZA +/- CTX 
Morton 
[69] 
2000 CS 
4 
mg/Kg/day 
SLE 3 years 43 CyA 
CyA effective in the 
management of 
thrombocytopenia but not of 
other lupus manifestations 
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(arthralgia, arthritis, myalgia, 
fatigue) 
Dammacco 
[68] 
2000 RCT 
5 
mg/Kg/day 
SLE 24 months 18 
CyA + PDN 
PDN 
CyA effective as steroid-sparing 
agent in SLE 
Hallegua 
[87] 
2000 CS 
3.8 
mg/Kg/day 
Membranous nephritis 
Disease activity 
12 months 10 CyA 
CyA effective in reducing 
proteinuria and and increasing 
serum albumina, no significant 
changes in SLEDAI score  
Duarte-Salazar 
[98] 
2000 CR 
3.5 
mg/Kg/day 
Pure red cell aplasia 6 months 1 CyA + steroids 
CyA effective in the treatment of 
pure red cell aplasia 
Tam 
[88] 
2001 CS 
5 
mg/Kg/day 
Type IV lupus nephritis 48 months 17 CyA + steroids 
CyA + steroids effective in lupus 
nephritis, with reduction of 
proteinuria, increase of serum 
albumin and histological 
improvement  
Atzeni 
[97] 
2003 CR 200 mg/day Pure red cell aplasia 2 years 1 CyA + steroids 
CyA effective in the treatment of 
pure red cell aplasia 
Hu 
[89] 
2003 CS 
5 
mg/Kg/day 
Membranous 
nephropathy 
36 months 24 CyA 
CyA effective in inducing 
complete remission in 52.2% of 
patients, partial remission in 
43.3% 
Singh 
[96] 
2004 CR 300 mg/day Aplastic anaemia 4 months 1 
CyA + steroids 
+ CTX 
CyA effective in the treatment of 
aplastic anemia 
Arcasoy 
[99] 
2005 CR 
5 
mg/Kg/day 
Pure red cell aplasia 3 months  1 CyA + MMF 
CyA effective in the treatment of 
pure red cell aplasia 
Wang 
[95] 
2005 CR 
3 
mg/Kg/day 
Refractory haemolytic 
anaemia 
2 months 1  CyA + steroids 
CyA effective in the treatment of 
refractory haemolytic anaemia 
Moroni 
[82] 
2006 RCT 
4 
mg/Kg/day 
Proliferative lupus 
nephritis 
4 months 69 
CyA 
AZA 
CyA and AZA equally effective 
as maintenance treatment of 
proliferative lupus nephritis 
Quartuccio 
[93] 
2006 CS 
3-5 
mg/Kg/day 
Thrombocytopenia 
23.5 
months 
6 CyA + steroids 
CyA effective in the 
management of 
thrombocytopenia 
Ogawa 2007 CS 2.5 Refractory lupus 30 weeks 9 CyA + steroids CyA + steroids effective in 
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CyA: cyclosporine A; CTX: cyclophosphamide; PDN: prednisone;  MTX: methotrexate; AZA: azathioprine; MMF: mycophenolate mofetil; PE: 
plasma exchange: SLE: systemic lupus erythematosus; LE: lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity index; 
NR: not reported; ANA: anti-nuclear antibodies; anti-dsDNA: anti-double stranded DNA antibodies. 
 
 
[78] mg/Kg/day nephritis refractory lupus nephritis, with 
reduction of proteinuria 
Rihova 
[77] 
2007 CS 
5 
mg/Kg/day 
Lupus nephritis 
85.6 
months 
31 CyA 
CyA effective in reducing 
proteinuria and stabilizing renal 
function 
Austin 
[90] 
2009 RCT NR 
Membranous lupus 
nephritis 
12 months 42 
CyA 
CTX 
PDN 
CyA more effective than PDN 
but less effective than CTX in 
the maintenance treatment of 
proliferative lupus nephritis 
Zavada 
[83] 
2010 RCT 
4-5 
mg/Kg/day 
Proliferative lupus 
nephritis 
18 months 40 
CyA 
CTX 
CyA as effective as CTX in the 
induction and maintenance 
treatment in patients with 
proliferative lupus nephritis 
Ogawa 
[79] 
2010 CS 
2.5 
mg/Kg/day 
Disease activity 
21.5 
months 
55 CyA 
CyA effective in reducing 
SLEDAI and flare rate 
Kamijo 
[80] 
2011 CS 
2.5 
mg/Kg/day 
Proliferative lupus 
nephritis 
2 years 11 CyA 
CyA effective as treatment of 
proliferative lupus nephritis 
Zavada 
[84] 
2014 RCT 
4.5 
mg/Kg/day 
Proliferative lupus 
nephritis 
7.7 years 38 
CyA 
CTX 
CyA and CTX equally effective 
at long-term as treatment of 
proliferative lupus nephritis 
Takahashi 
[100] 
2015 CS NR 
Lupus 
haemophagocytic 
syndrome 
NR 3 CyA + steroids 
CyA effective in the treatment of 
lupus haemophagocytic 
syndrome 
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Table 4. Studies on cyclosporine A in systemic sclerosis. 
 
Author [Ref] Year 
Study 
design  
CyA dose Follow-up N of patients Treatment groups Outcome 
Zachariae 
[109] 
1990 PC 
7.5 
mg/Kg/day 
16 months 10 CyA 
CyA effective in reducing skin 
thickening in 20% of patients 
Clements 
[108] 
1993 PC 
5 
mg/Kg/day 
48 week 10 CyA 
CyA effective in reducing skin 
thickening but not in controlling 
lung and cardiac involvement 
Denton 
[115] 
1994 RCT 
2.5 
mg/Kg/day 
1 year 20 
CyA + iloprost 
Iloprost + placebo 
CyA effective in reducing skin 
thickening and controlling 
microvascular and oesophageal 
involvement 
Filaci 
[111] 
1999 CR 
3-4 
mg/Kg/day 
- 3 CyA SRC in all cases 
Morton 
[212] 
2000 CS 
3.4 
mg/Kg/day 
- 
 
16 CyA 
CyA effective in reducing skin 
thickening in half of patients 
Roch 
[110] 
2004 CR 
2 
mg/Kg/day 
5 years 1 CyA 
CyA effective in reducing skin 
thickening 
Zentilin  
[112] 
2004 CR 
2.5 
mg/Kg/day 
6 months 2 CyA 
CyA effective in controlling 
oesophageal involvement 
Ando 
[113] 
2013 CR 
100-150 
mg/day 
2-4 years 2 CyA 
Stabilization of lung function 
with CyA as maintenance 
treatment 
 
CyA: cyclosporine A; SRC: scleroderma renal crisis; CS: case-series; PC: prospective cohort; CR: case-report; RCT: randomized controlled trial.  
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Table 5. Studies on cyclosporine A in inflammatory myopathies. 
 
Author [Ref] Year 
Study 
design  
CyA dose Follow-up N of patients Treatment groups Outcome 
Grau 
[116] 
1994 CC 
5 
mg/Kg/day 
24 months 10 DM 
CyA 
Steroids + AZA 
CyA effective in inducing 
remissions more quickly than 
steroids + AZA 
Vencovsky 
[117] 
2000 RCT 
3-3.5 
mg/Kg/day 
6 months 
20 DM 
16 PM 
CyA + steroids 
MTX + steroids 
CyA and MTX equally effective in 
the management of muscle 
involvement 
Kotani 
[119] 
2005 CR NR NR 1 DM CyA + CTX + steroids 
CyA + steroids not effective in the 
management of ILD 
Takada 
[122] 
2005 RC 150 mg/day 24 months 53 DM/PM 
CyA + steroids 
Steroids 
CyA + steroids more effective than 
steroids alone in managing 
PM/DM  
Sakamoto 
[124] 
2005 CR 
100-150 
mg/day 
7.5 years 1 DM CyA + steroids 
CyA + steroids effective in the 
management of ILD 
Mii 
[118] 
2006 CR 
1 
mg/Kg/day 
6 months 1 DM CyA + steroids 
CyA + steroids effective in the 
management of dysphagia 
Terao 
[121] 
2007 CR 125 mg/day 4 years 1 DM CyA + steroids 
CyA + steroids effective in the 
management of 
pneumomediastinum 
Kotani 
[120] 
2008 CS 
4 
mg/Kg/day 
2 weeks 16 DM CyA + steroids 
CyA effective as early treatment of 
DM-ILD 
Kim 
[213] 
 
2009 CR 100 mg/day NR 6 DM CyA + steroids 
CyA effective in the management 
of 5 out of 6 patients with DM 
complicated by 
pneumomediastinum 
Kotani 
[214] 
2011 CS 
4 
mg/Kg/day 
12 months 14 DM CyA + steroids 
CyA + steroids effective in 
improving LFT and HRCT  
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Ingegnoli 
[127] 
2012 CC 
5 
mg/Kg/day 
12 months 15 PM 
CyA + steroids 
CTX + steroids 
No significant difference between 
CyA and CTX groups in the 
progression rate of ILD at HRCT 
Suzuki 
[126] 
2013 CR 150 mg/day NR 3 DM CyA + steroids + CTX 
CyA + steroids + CTX effective in 
the management of DM-ILD 
Cavagna 
[125] 
2013 CS 
3 
mg/Kg/day 
96 months 18 PM CyA + steroids 
CyA effective in the management 
of DM-ILD 
Labirua-
Iturburu 
[123] 
2013 CS 
2.5-5 
mg/Kg/day 
24 months 15 PM 
CyA 
Tacrolimus 
CyA effective in the management 
of DM-ILD 
 
 
DM: dermatomyositis; PM: polymyositis; ILD: interstitial lung disease; CyA: cyclosporine A; MTX: methotrexate; CTX: cyclophosphamide; AZA: 
azathioprine; LFT: lung function test; HRCT: high resolution CT scan of the chest; CC: case cohort; RC: retrospective cohort; CS: case-series; CR: 
case-report; RCT: randomized controlled trial; NR: not reported.  
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Table 6. Studies on cyclosporine A in systemic vasculitides.  
Author [Ref] Year 
Study 
design  
 
CyA dose Follow-up 
N of 
patients 
Treatment groups Outcome 
Wendling 
[134] 
1985 CR 
PMR 
TA 
3 
mg/Kg/day 
3 months 2 CyA + steroids 
CyA effective in the 
management of relapsing 
PMR and TA 
Gremmel 
[128] 
1988 CR GPA 
5 
mg/Kg/day 
27 months 2 CyA + steroids 
CyA effective of 
pulmonary and renal 
involvement 
Harley 
[130] 
1990 CR GPA NR 6 months 1 CyA 
CyA effective in the 
management of GPA 
Borleffs 
[129] 
1990 CR GPA 
5 
mg/Kg/day 
2 years 1 CyA + steroids 
CyA effective in the 
management of severe 
GPA with renal 
involvement 
Fullerton 
[138] 
1991 CR TA 
4 
mg/Kg/day 
3 months 1 CyA 
CyA effective in the 
management of pyoderma 
gangrenosum associated 
with TA 
Schaufelberger 
[133] 
1998 RCT GCA 
2 
mg/Kg/day 
6 months 22 
CyA + steroids 
CyA 
CyA not effective as 
additive agent in GCA 
McDermott 
[132] 
1998 CR EGP 
3.5 
mg/Kg/day 
5 months 1 CyA + steroids 
CyA effective in the 
management of severe 
EGP 
Fearfield 
[137] 
1999 CR TA 
5 
mg/Kg/day 
18 months 1 
CyA + steroids + 
minocycline 
CyA effective in the 
management of pyoderma 
gangrenosum associated 
with TA 
Horigome 
[136] 
1999 CR TA 
4.3 
mg/Kg/day 
4 years 1 CyA + steroids 
CyA effective in the 
management of TA 
Inoue 
[131] 
2000 CR GPA 
100 
mg/day 
NR 1 
CyA + CTX + 
steroids 
CyA effective in the 
management of GPA 
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PMR: polymyalgia rheumatica; GPA: granulomatosis with polyangiitis; GCA: giant cell arteritis; TA: Takayasu’s arteritis; EGP: esinophilic 
granulomatosis with polyangiitis; CyA: cyclosporine A; CTX: cyclophosphamide; CR: case-report; RCT: randomized controlled trial; NR: not 
reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
Table 7. Studies on cyclosporine A in Behçet’s disease.  
 
Author 
[Ref] 
Year 
Study 
design 
CyA dose N of patients Follow-up Treatment groups Outcome 
BenEzra 
[142] 
1988 CC 
5 
mg/Kg/day 
40 3 years 
CyA 
Corticosteroids 
Leukeran 
CyA more effective than 
conventional treatment in the 
management of ocular 
manifestations of BD 
Masuda 
[143] 
1989 RCT 
10 
mg/Kg/day 
96 16 weeks 
CyA 
Colchicine 
CyA more effective than colchicine 
in reducing the frequency and 
severity of ocular attacks, of oral 
aphthous ulcer and dermal lesions  
Ozyazgan 
[141] 
1992 CC 
5 
mg/Kg/day 
23 34 months 
CyA 
CTX 
CyA more effective than CTX in the 
management of BD-associated 
uveitis at 6 months 
Avci 
[148] 
1997 CS 
5 
mg/Kg/day 
24  6 months CyA 
CyA effective on mucocutaneous 
manifestations of BD 
Cantini 
[147] 
1999 PC 
5 
mg/Kg/day 
7 48 months CyA 
CyA effective in the management of 
thrombophlebitis associated with BD 
Yamada 
[144] 
2010 RCT 
3-5 
mg/Kg/day 
37 6 months 
CyA  
IFX 
CyA less effective than IFX in 
reducing episodes of uveitis in BD 
 
BD: Behçet’s disease; CyA: cyclosporine A; CTX: cyclophosphamide; IFX: infliximab; CS: case-series; CC: case-control; RCT: randomized 
controlled trial; PC: prospective cohort.  
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Table 8. Studies on cyclosporine A in adult onset Still’s disease. 
 
Author [Ref] Year 
Study 
design 
CyA dose Follow-up N of patients Treatment group(s) Outcome 
Mori 
[155] 
1993 CR NR NR 1 CyA + steroids 
Improvement of Still’s disease-
associated DIC with CyA 
Park 
[156] 
2004 CR 
2-3 
mg/Kg/day 
12 months 1 CyA + steroids + IvIg 
Improvement of Still’s disease-
associated DIC with CyA 
Hamidou 
[157] 
2005 CR NR NR 1 CyA 
Improvement of Still’s disease-
associated haemophagocytic 
syndrome with CyA 
Her 
[159] 
2007 CR 
300 
mg/day 
48 months 1 CyA 
Improvement of Still’s disease-
associated acquired 
amegakaryocytic 
thrombocytopenia with CyA 
Nagashima 
[160] 
2008 CR 
3 
mg/Kg/day 
NR 2 CyA 
Improvement of Still’s disease-
associated hepatic failure with 
CyA 
Mizrahi 
[158] 
2009 CR 
3 
mg/Kg/day 
8 months 1 
CyA + MMF  + 
steroids 
Improvement of Still’s disease-
associated relapsing macrophage 
activating syndrome with CyA 
Mitamura 
[153] 
2009 CS 
Adjusted 
dose 
12.4 months 7 CyA 
Induction of remission in 6/7 
patients with Still’s disease 
 
CyA: cyclosporine A; DIC: disseminated intravascular coagulation; NR: not reported; MMF: mycophenolate mofetil; IvIg: intra-venous 
Immunoglobulins; CR: case-reports; CS: case-series.  
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Table 9. Studies on cyclosporine A in Sjogren’s syndrome or dry eye disease. 
 
Author 
[Ref] 
Year 
Study 
Design 
CyA dose N of patients  Follow-up Treatment groups Outcome 
Drosos 
[170] 
1986 CS 
5 
mg/Kg/day 
20 SSj 12 months CyA 
CyA effective on xerostomia but not 
minor salivary gland histology  
Drosos 
[171] 
1986 CC 
5 
mg/Kg/day 
20 SSj 6 months 
CyA 
Placebo 
CyA effective on histology but not 
xerostomia 
Stevenson 
[165] 
2000 RCT 
Topical 
0.05% - 
0.1% - 
0.2% - 
0.4% 
162 dry eye 
disease 
16 weeks 
CyA 
Placebo 
CyA effective on signs and symptoms 
of xerophtalmia  
Sall 
[167] 
2000 RCT 
Topical 
0.05% - 
0.1% 
877 dry eye 
disease 
6 months 
CyA 
Placebo 
CyA effective on objective and 
subjective measures of xerophtalmia 
Barber 
[166] 
2005 CS 
Topical 
0.1% 
412 dry eye 
disease 
3 years CyA 
CyA safe and effective on 
xerophtalmia 
Roberts 
[168] 
2007 RCT 
Topical 
0.05% 
30 dry eye 
disease 
6 months 
CyA 
Punctual occlusion 
CyA + punctual 
occlusion 
 
CyA effective on ocular surface 
health, additive effects with punctual 
occlusion 
Kim 
[169] 
2009 RCT 
Topical 
0.05% 
150 dry eye 
disease 
3 months 
CyA 
Vitamin A eye drops 
CyA as effective as vitamin A eye 
drops for dry eye disease 
 
 
CyA: cyclosporine A; SSj: Sjogren’s syndrome; CS: case-series; CC: case-control; RCT: randomized controlled trial.  
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Table 10. Studies on cyclosporine A in macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. 
 
Author [Ref] Year 
Study 
design 
N of patients Treatment group(s) Outcome 
Mouy 
[179] 
1996 CS 7 CyA CyA effective as first line or second line tool in MAS 
Ravelli 
[180] 
1996 CR 1 CyA CyA effective as second line tool in MAS  
Stephan 
[181] 
2001 CS 18 
CyA 
IvIg 
Steroids 
CyA effective as first and second line tool in MAS 
associated with sJIA 
Sawhney 
[182] 
2001 CS 7 
CyA + steroids 
CTX + steroids 
Anti-thymocyte 
globulin + steroids 
CyA + steroids effective in MAS 
Kounami 
[183] 
2005 CS 5 CyA CyA effective as second line tool in MAS 
Cortis 
[184] 
2006 CS 9 
CyA + steroids 
ETN 
CyA + steroids effective in MAS 
You 
[185] 
2006 CR 1 CyA CyA effective as second line tool in MAS  
Lin 
[186] 
2012 CS 4 
CyA + steroids 
IvIg + steroids 
CyA + steroids effective in MAS 
 
 
CyA: cyclosporine A; IvIg: intra-venous Immunoglobulins; CTX: cyclophosphamide; ETN: etanercept; CS: case-series; CC: case-control; CR: 
case-report; MAS: macrophage activation syndrome. 
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Table 11. The toxicity of cyclosporine A in patients with rheumatoid arthritis [207].  
 
Toxicity Frequency (%)* 
Constitutional symptoms 
  Fatigue 
  Fever 
  Influenza-like symptoms 
  Arthralgias/arthritis 
 
3-12% 
0-4% 
0-6% 
0-5% 
Reno-urinary toxicity 
  Creatine elevation > 30% 
  Creatinine elevation > 50% 
  Dysuria 
  Urinary tract infection 
 
13-55% 
3-26% 
0-11% 
0-19% 
Cardiovascular toxicity 
  Hypertension 
  Arrythmias 
  Chest pain 
 
2-26% 
1-6% 
1-6% 
Gastrointestinal toxicity 
  Gum hyperplasia 
  Gingivitis 
  Stomatitis 
  Nausea 
  Vomiting 
  Dyspepsia 
  Anorexia 
  Diarrhea 
Abdominal pain 
 
1-4% 
0-4% 
5-16% 
14-24% 
5-14% 
4-12% 
0-3% 
8-18% 
7-15% 
Skin and appendage toxicity 
  Hypertrichosis   
  Alopecia 
  Bullous eruption 
  Rash 
  Purpura 
 
0-19% 
0-4% 
0-4% 
7-12% 
0-4% 
Nervous system toxicity 
  Dizziness 
  Headache 
  Migraine 
  Paresthesia 
  Depression 
  Insomnia 
 
3-8% 
9-25% 
0-3% 
1-11% 
1-6% 
1-4% 
Respiratory toxicity 
  Rhinitis 
 
0-10% 
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  Sinusitis 
  Pharingitis 
  Coughing 
  Dyspnea 
  Bronchitis 
  Pneumonia 
3-8% 
3-6% 
3-7% 
1-5% 
0-3% 
0-4% 
 
*: considering controlled clinical trials. 
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Table 12. The interaction of cyclosporine A with other pharmacological compounds. 
 
Increased CyA blood levels Decreased CyA blood levels 
 
Enhanced nephrotoxicity 
 
Allopurinol 
Antimalarials 
Bosentan 
Clarythromycin 
Diltiazem 
Erythromycin 
Fluconazole 
Imatinib 
Ketoconazole 
Methylprednisolone (High dose) 
Methotrexate 
Nicardipine 
Verapamil 
Barbiturates 
Carbamazepin 
Rifampin 
Rifabutin 
Isoniazid 
Nafcillin 
Sulfasalazine 
Aminoglycosides 
Amphotericin B 
Ciprofloxacin 
Sulfonamides 
ACE inhibitors 
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